Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Adenocarcinoma
/ drug therapy
Antineoplastic Agents
/ chemistry
BRCA2 Protein
/ genetics
Cell Line, Tumor
DNA Damage
/ drug effects
Drug Discovery
Drug Synergism
Homologous Recombination
/ drug effects
Humans
Models, Molecular
Pancreatic Neoplasms
/ drug therapy
Phthalazines
/ chemistry
Piperazines
/ chemistry
Poly(ADP-ribose) Polymerase Inhibitors
/ chemistry
Protein Interaction Maps
/ drug effects
Rad51 Recombinase
/ metabolism
Small Molecule Libraries
/ chemistry
Synthetic Lethal Mutations
/ drug effects
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
12 03 2020
12 03 2020
Historique:
pubmed:
11
2
2020
medline:
1
9
2020
entrez:
11
2
2020
Statut:
ppublish
Résumé
Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with
Identifiants
pubmed: 32037829
doi: 10.1021/acs.jmedchem.9b01526
pmc: PMC7997579
doi:
Substances chimiques
Antineoplastic Agents
0
BRCA2 Protein
0
Phthalazines
0
Piperazines
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Small Molecule Libraries
0
Rad51 Recombinase
EC 2.7.7.-
olaparib
WOH1JD9AR8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2588-2619Références
Mol Cell. 2001 Feb;7(2):273-82
pubmed: 11239456
EMBO Mol Med. 2013 Mar;5(3):353-65
pubmed: 23341130
Nature. 2002 Nov 21;420(6913):287-93
pubmed: 12442171
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Curr Cancer Drug Targets. 2018;18(4):337-346
pubmed: 28669337
Ther Adv Med Oncol. 2018 Jul 13;10:1758835918786658
pubmed: 30023007
IUBMB Life. 2017 Dec;69(12):929-937
pubmed: 29171189
Genetics. 1968 May;59(1):37-44
pubmed: 5683639
Nat Rev Clin Oncol. 2018 Sep;15(9):564-576
pubmed: 29955114
Toxicology. 2003 Nov 15;193(1-2):91-109
pubmed: 14599770
DNA Repair (Amst). 2008 May 3;7(5):686-93
pubmed: 18243065
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Nat Rev Drug Discov. 2011 May;10(5):351-64
pubmed: 21532565
ACS Chem Biol. 2017 Oct 20;12(10):2491-2497
pubmed: 28841282
Trends Cancer. 2019 Jan;5(1):11-29
pubmed: 30616753
Eur J Med Chem. 2019 Mar 1;165:80-92
pubmed: 30660828
Nucleic Acids Res. 2010 Jan;38(1):82-96
pubmed: 19875419
Genes Cells. 2008 May;13(5):471-81
pubmed: 18429819
Oral Oncol. 1998 Nov;34(6):524-8
pubmed: 9930366
Genetics. 1946 May;31:269-90
pubmed: 20985721
J Biol Chem. 1997 Dec 19;272(51):31941-4
pubmed: 9405383
Drugs. 2015 Feb;75(2):231-40
pubmed: 25616434
Nat Genet. 1996 May;13(1):22-3
pubmed: 8673099
J Med Chem. 2010 Aug 12;53(15):5782-91
pubmed: 20684611
Nat Rev Cancer. 2005 Sep;5(9):689-98
pubmed: 16110319
Curr Protoc Pharmacol. 2004 Sep 1;Chapter 12:Unit 12.8
pubmed: 22294120
J Med Chem. 2013 Aug 22;56(16):6434-56
pubmed: 23909910
Cell Mol Life Sci. 2018 Sep;75(18):3381-3392
pubmed: 30003270
Cell. 1990 May 18;61(4):723-33
pubmed: 2188733
Hum Mol Genet. 1997 Jan;6(1):53-8
pubmed: 9002670
Genes Dev. 1991 Jun;5(6):958-69
pubmed: 2044962
J Natl Cancer Inst. 1998 Jul 1;90(13):978-85
pubmed: 9665145
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138